Canadian Medical Isotope Ecosystem’s Post

The Calibr-Skaggs Institute for Innovative Medicines, a nonprofit research institute founded by Scripps Research President and CEO Peter Schultz, joined Scripps Research in 2018 as its drug discovery division. As a world-class nonprofit “bench to bedside” drug discovery engine, Calibr delivers groundbreaking solutions to unmet medical needs by uniting the creativity of fundamental discovery with highly focused R&D capabilities and expertise. Learn more: https://ow.ly/xl0F50UtCCV

Bruce Power has signed a 10-year extension to a Master Service Agreement (MSA) with Kinectrics Inc. in support of continued excellence in its operation, Life-Extension Program and the production of cancer-fighting medical isotopes. Learn more here: https://lnkd.in/gHc3u-P5

Great news for miDiagnostics, who secured a €30 Million Series D funding round to advance an innovative sterility test and other quality control tests for use in the biopharma industry! The funding round is led by Thermo Fisher Scientific and strengthened by Alychlo, VMF Invest and Pamica. Katleen Verleysen, CEO at miDiagnostics, says: "We advance our mission to revolutionize sterility testing in the biopharma sector. This funding will enable us to expedite our development efforts and leverage Thermo Fisher’s expertise for the commercialization of our pioneering products.” Exciting times for this imec spin-off! Congratulations!

LCS sponsored the first Asian American Architects and Engineers Association panel focused on the Life Sciences industry in Orange County. This all-star panel included Raul Garcia from Edwards Lifesciences, Gul Dusi from JLL, Karin Koch from Koch Advisory, Tom Lam from Luminous Capital Management, and Jonathan Tu from FluxErgy. Kelly Stringer lead the discussion and asked the panel to give insight into the Life Sciences industry in Orange County. Panelists identified that due to Orange County cities and universities collaborating to bring innovative companies to Orange County, the outlook is bright for the industry with a plan to attract companies including: medical device manufacturers, biopharmaceuticals, defense solutions, and innovative sustainability solutions. Gul spoke about the recent update send out by JLL that has a positive outlook on the Orange County and Los Angeles area in the next few years.

Medtech - A hidden gem? Yes it is, according to Carl Borrebaeck and the panel he moderated at Day 1 of BioStock Life Science Summit. The discussion highlighted key criteria for investing in medtech companies, including IP, business models, reimbursement strategies and regulatory pathways. A big thank you to: Karin Leire, Segulah Medical Acceleration Fiona Law, Potter Clarkson Magnus Holm, Peppermint Venture Partners GmbH Hanna Sjöström, Neola Medical

We are pleased to share one of the great presentations from the 24th Annual Biotech in Europe Forum #Sachs_BEF eleva presentation by Björn Cochlovius, CEO. Eleva is a clinical-stage biopharmaceutical that strives to bring novel therapies to patients in need together with partners as well as independently. We harness the outstanding capabilities of our moss-based expression platform to create candidates few or no one else can and advance them into clinical development. Our current two proprietary programs currently focus on complement disorders and enzyme replacement therapies. Factor H is a key complement control protein in humans. Eleva is advancing its proprietary, moss-expressed Factor H (CPV-104) program into clinical development with an initial focus on C3 Glomerulopathy (C3G). It has the potential to restore the natural balance in the complement system, thereby controlling over-activation while retaining its protective properties. Beyond C3G, the program has shown therapeutic potential in a range of indications including atypical hemolytic uremic syndrome (aHUS) and the dry form of age-related macular degeneration (dry AMD). Recombinant human Factor H (Factor H) indicated for complement-associated disorders has been developed to precommercial GMP scale and will be entering clinical trials in Q4/2024. Eleva’s glyco-improved form of alpha Galactosidase - aGal (RPV-001) expressed in moss, has shown promising effects in a clinical Ph1b trial. Eleva’s proprietary aGal (RPV-001) exhibits superior cell uptake, prolonged efficacy and improved long-term safety. The recombinant aGal (RPV-001) program is a prime example for the positive impact of our proprietary expression system on key product capabilities otherwise unattainable with conventional production cell lines. Eleva’s team combines decades of scientific and industry experience. We take on the challenge to successfully develop almost any complex, difficult protein with efficient and effective human glycosylation! We relentlessly pursue those therapeutic opportunities, where our technology and expertise can make a key difference and deliver the next-level medicines to patients. View here: https://lnkd.in/d5p4FhWJ #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Can we make allosteric modulators that change a GPCR's preferred G protein? Yes! 💥 Small molecules that bind the GPCR-transducer interface change G protein subtype selectivity in predictable ways, enabling rational drug design. I'm thrilled to share how much we have learned in the lab's 1st preprint. Check it out here! 👉 https://bit.ly/41ab0AW This was a collaborative effort in and out of the lab. Led by superstar students Madelyn Moore and Kelsey Person and made possible by the brilliance of Steve Olson and his med chem group at Sanford Burnham Prebys. I am hugely grateful to our entire team at UMN Pharmacology, SBP, and beyond, including Ezequiel Marron Fernandez de Velasco, Abigail Alwin, Campbell Krusemark, Noah Foster, Michael Jackson, Asuka Inoue, Caroline Ray, Lawrence Barak, and Michael Sheedlo. Some highlights below!

My poster sessions are on Friday Society for Immunotherapy of Cancer (SITC). If you'd like to hear about 'LS Finder' and are interested in #spatialbiology #datascience please stop by posters 205 Development of an Algorithm (‘LS Finder’) for Identifying Lymphoid Structures, TLS and Lymphoid Aggregates, Using Immune Cell Spatial Coordinates and 1219 Analysis of PD1+ T Cells and Lymphoid Structure(TLS) Presence in Pleural Mesothelioma Using Spatial and Machine Learning Approaches. https://lnkd.in/gsevcGMD

Fascinating study showing how #GPCRs continue to present a potentially huge set of targets for development of novel medicines. #pharmacology #neuroscience

Our Genmab colleague Cristine Steen-Louws, is presenting at the EBF Open Symposium in Barcelona during the Patient-Centric Trials (PCT) & DBS Technology session. Cristine will share insights into applying microsampling in non-clinical studies in combination with Ligand Binding Assays, discussing what it takes to develop sustainable solutions while upholding high-quality standards in the bioanalytical lab.